Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis  

作　　者：Mohamed Abdel-Samiee Essam Salah Ibrahim Mohamed Kohla Eman Abdelsameea Mohsen Salama 

机构地区：[1]Department of Hepatology and Gastroenterology,National Liver Institute,Menoufia University,Shebin El-Kom 32511,Egypt [2]Department of Medicine,RCSI Medical University of Bahrain,Adliya 15503,Bahrain

出　　处：《World Journal of Gastrointestinal Pharmacology and Therapeutics》2024年第6期18-27,共10页世界胃肠药理与治疗学杂志（英文）

摘　　要：The global incidence of nonalcoholic fatty liver disease(NAFLD)is escalating considerably.NAFLD covers a range of liver conditions from simple steatosis to the more severe form known as nonalcoholic steatohepatitis,which involves chronic liver inflammation and the transformation of hepatic stellate cells into myofibroblasts that generate excess extracellular matrix,leading to fibrosis.Hepatocyte ballooning is a key catalyst for fibrosis progression,potentially advancing to cirrhosis and its decompensated state.Fibrosis is a critical prognostic factor for outcomes in patients with NAFLD;therefore,those with substantial fibrosis require timely intervention.Although liver biopsy is the most reliable method for fibrosis detection,it is associated with certain risks and limitations,particularly in routine screening.Consequently,various noninvasive diagnostic techniques have been introduced.This review examines the increasing prevalence of NAFLD,evaluates the noninvasive diagnostic techniques for fibrosis,and assesses their efficacy in staging the disease.In addition,it critically appraises current and emerging antifibrotic therapies,focusing on their mechanisms,efficacy,and potential in reversing fibrosis.This review underscores the urgent need for effective therapeutic strategies,given the dire consequences of advanced fibrosis.

关 键 词：Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis MYOFIBROBLASTS FIBROSIS Antifibrotic pharmacotherapy Nonalcoholic fatty liver disease treatment strategies Emerging treatments for nonalcoholic steatohepatitis 

分 类 号：R575.1[医药卫生—消化系统]